| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/26/2009 | WO2009025477A1 Indole compounds as an inhibitor of cellular necrosis |
| 02/26/2009 | WO2009025358A1 Heterocyclic compound and use thereof |
| 02/26/2009 | WO2009025196A1 Foxm1 peptide and medicinal agent comprising the same |
| 02/26/2009 | WO2009025168A1 Sugar-modified liposome containing compound for contrast agent and contrast agent |
| 02/26/2009 | WO2009025117A1 Cdca1 peptide and pharmaceutical agent comprising the same |
| 02/26/2009 | WO2009025116A1 Cdh3 peptide and medicinal agent comprising the same |
| 02/26/2009 | WO2009024924A1 Albumin for treating cancer and a pharmaceutical composition comprising the combination of an anti-neoplastic agent and albumin |
| 02/26/2009 | WO2009024825A1 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors |
| 02/26/2009 | WO2009024824A1 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders |
| 02/26/2009 | WO2009024820A2 Therapeutic treatment 014 |
| 02/26/2009 | WO2009024771A2 Materials and methods for treating cancers which express folate receptors |
| 02/26/2009 | WO2009024763A2 Combination therapy |
| 02/26/2009 | WO2009024667A2 Antitumour combinations containing a vegf inhibiting agent and irinotecan |
| 02/26/2009 | WO2009024631A2 A combination of inhibitors of tgfbeta-1 and matrix metalloproteins for use in the treatment of bone metastases, bone resorption and hypercalcaemia |
| 02/26/2009 | WO2009024613A1 Tetracyclic indolopyridines as eg5 inhibitors |
| 02/26/2009 | WO2009024542A2 Purin derivatives for use in the treatment of fab-related diseases |
| 02/26/2009 | WO2009024348A1 Method for activating regulatory t-cells |
| 02/26/2009 | WO2009024332A1 Pyridoneamide derivatives as focal adhesion kinase (fak) inhibitors and their use for the treatment of cancer |
| 02/26/2009 | WO2009024221A1 6-thioxo-pyridazine derivatives |
| 02/26/2009 | WO2009024190A1 Indolopyridines as inhibitors of the kinesin spindle protein (eg5 ) |
| 02/26/2009 | WO2009024095A1 Method of making and administering quinoline derivatives as anti-cancer agents |
| 02/26/2009 | WO2009023978A1 Pyrazolo [3,4 -d] pyrimidine compounds and their use as modulators of protein kinase |
| 02/26/2009 | WO2009023961A1 Pthrp, its isoforms and antagonist thereto in the diagnosis and treatment of disease |
| 02/26/2009 | WO2009023959A1 Calmodulin-binding peptides that reduce cell proliferation in cancer and smooth muscle proliferation diseases |
| 02/26/2009 | WO2009023955A1 Cytotoxicity mediation of cells evidencing surface expression of cd9 |
| 02/26/2009 | WO2009023903A1 Compositions comprising phospholipids |
| 02/26/2009 | WO2009008992A3 Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2 |
| 02/26/2009 | WO2009006541A3 Proteinases destroy cancer tumor's solid structure and kill cancer cells locally |
| 02/26/2009 | WO2009001046A3 [11c]methoxy-radiolabelled 2,3',4,5'-tetramethylstilbene (tms) and its preparation and use |
| 02/26/2009 | WO2008154004A3 Inhibition of tumor metastases using protein kinase c (pkc) inhibitors |
| 02/26/2009 | WO2008140553A3 Mapk/erk kinase inhibitors |
| 02/26/2009 | WO2008136848A3 Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease |
| 02/26/2009 | WO2008136736A3 Immunoregulatory structures from normally occurring proteins |
| 02/26/2009 | WO2008090585A3 Soluble forms of inclusion complexes of histone deacetylase inhibitors and cyclodextrins, their preparation processes and uses in the pharmaceutical field |
| 02/26/2009 | WO2008064004A3 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml) |
| 02/26/2009 | WO2008045604A3 Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
| 02/26/2009 | WO2008014060A3 Microparticle |
| 02/26/2009 | US20090055944 Human monoclonal antibodies to be programmed death ligand 1 (pd-l1) |
| 02/26/2009 | US20090054720 Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer |
| 02/26/2009 | US20090054622 Peptide variants of the tumor marker MUC1 and their application |
| 02/26/2009 | US20090054516 Composition for treating cancer cells and synthetic method for the same |
| 02/26/2009 | US20090054514 (3-Amino-6-phenyl-benzofuran-2-yl)-(2,4-dichloro-phenyl)-methanone; antiprolifrative, anticarcinogenic, antitumor agent; lymphomas, sarcomas, and leukemias |
| 02/26/2009 | US20090054503 Composition |
| 02/26/2009 | US20090054488 Isomigrastatin Analogs In The Treatment Of Cancer |
| 02/26/2009 | US20090054484 Substituted heteroaryl benzofuran acids |
| 02/26/2009 | US20090054482 Method of making and administering quinoline derivatives as anti-cancer agents |
| 02/26/2009 | US20090054472 Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof |
| 02/26/2009 | US20090054469 Quinazolinone derivatives and their use as b-raf inhibitors |
| 02/26/2009 | US20090054467 Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases |
| 02/26/2009 | US20090054464 Hdac inhibitor |
| 02/26/2009 | US20090054454 Benzofuranyl- and benzothienyl- piperazinyl quinolines and methods of their use |
| 02/26/2009 | US20090054452 Thienopyridine Derivatives and the Use Thereof as Hsp90 Modulators |
| 02/26/2009 | US20090054451 Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity |
| 02/26/2009 | US20090054438 Compositions and methods for inhibiting growth and metastasis of melanoma |
| 02/26/2009 | US20090054436 anticarcinogenic compounds; ; N-(4-(2-Aminopyridin-4-yloxy)-3-fluorophenyl)-2-bromoisonicotinamide, trifluoroacetic acid salt; inhibit the protein tyrosine kinase activity of growth factor receptors like Hepatocyte growth factor |
| 02/26/2009 | US20090054432 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors |
| 02/26/2009 | US20090054428 Novel pyrimidine derivatives 965 |
| 02/26/2009 | US20090054425 Protein kinase inhibitors |
| 02/26/2009 | US20090054424 Optically active pyridine derivative and a medicament containing the same |
| 02/26/2009 | US20090054420 Bicyclic-substituted amines as histamine-3 receptor ligands |
| 02/26/2009 | US20090054415 Combinations, methods and compositions for treating cancer |
| 02/26/2009 | US20090054411 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors |
| 02/26/2009 | US20090054409 [4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-morpholin-4-yl-methanone, used for treating rheumatoid arthritis in mammals |
| 02/26/2009 | US20090054407 such as 4-Methanesulfonyloxy-5-methoxy-7-[1H-5-(methylaminomethyl)indol-2-yl]isoindolinone, having an antitumor activity |
| 02/26/2009 | US20090054405 PI3 kinase modulators and methods of use |
| 02/26/2009 | US20090054398 Chemical compounds |
| 02/26/2009 | US20090054396 Substituted thiophenes and uses thereof |
| 02/26/2009 | US20090054395 focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride |
| 02/26/2009 | US20090054392 Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| 02/26/2009 | US20090054376 Benzofuran derivatives with therapeutic activities |
| 02/26/2009 | US20090054369 Pharmaceutical compositions of silicon-containing substituted adenosine nucleoside amide analogs |
| 02/26/2009 | US20090054366 RNAi MEDIATED KNOCKDOWN OF NUMA FOR CANCER THERAPY |
| 02/26/2009 | US20090054364 treating bladder cancer; transfecting with polynucleotide into urothelial cells; improved transfection efficiency with cationic lipids, cationic polymers or dendrimers; improve drug delivery with a solubilized cholesterol |
| 02/26/2009 | US20090054363 Genetic markers and methods for detecting and treating cancers |
| 02/26/2009 | US20090054361 Pot1 alternative splicing variants |
| 02/26/2009 | US20090054351 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
| 02/26/2009 | US20090054347 Kinin b1 receptor peptide agonists and uses thereof |
| 02/26/2009 | US20090054345 Template-Fixed Beta-Hairpin Peptidomimetics With Protease Inhibitory Activity |
| 02/26/2009 | US20090054336 Binding Agent |
| 02/26/2009 | US20090054333 Peptide inhibitors of cyclin-dependent kinase activity and uses thereof |
| 02/26/2009 | US20090054323 Ang-2 inhibitor peptides; use treating tumors, eye disorders, bone disorders, psoriasis; angiogenesis inhibitors; amino acid sequence WDPWT |
| 02/26/2009 | US20090054322 Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions |
| 02/26/2009 | US20090054318 Immunopotentiating Agent |
| 02/26/2009 | US20090053808 Compositions and methods for inhibiting the expression of anti-apoptopic genes |
| 02/26/2009 | US20090053341 Preventative and Treatment Effects of Morinda Citrifolia as an Aromatase Inhibitor |
| 02/26/2009 | US20090053330 solvent extraction, ultrafiltration, concentrating and drying to obtain an extract powder, irradiating with a far-infrared treatment; remove allergy-inducing agent urushiol; free of allergy side effect; anticarcinogenic agents |
| 02/26/2009 | US20090053308 Release-Control Composition |
| 02/26/2009 | US20090053305 Pharmaceutical Formulations |
| 02/26/2009 | US20090053302 Cancer treatments |
| 02/26/2009 | US20090053296 Using cell-mediated immune response to e6 and e7 peptides as diagnostic/prognostic indication of recurrence and/or development of cervical intraepithelial neoplasia (CIN) |
| 02/26/2009 | US20090053293 Nano Anticancer Micelles of Vinca Alkaloids Entrapped in Polyethylene Glycolylated Phospholipids |
| 02/26/2009 | US20090053264 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
| 02/26/2009 | US20090053252 Bimer or an oligomer of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins |
| 02/26/2009 | US20090053247 Biological materials and uses thereof |
| 02/26/2009 | US20090053241 inhibition of platelet derived growth factor receptor-beta (PDGFR beta ) on angiogenesis, and provides for treatment of angiogenesis; |
| 02/26/2009 | US20090053233 Cytotoxic Antibody Directed Against Type B Lymphoid Hematopoietic Proliferations |
| 02/26/2009 | US20090053231 Optical Disc Apparatus |
| 02/26/2009 | US20090053227 Prostate Specific Genes and The Use Thereof in Design of Therapeutics |
| 02/26/2009 | US20090053226 Compositions and methods for the treatment of tumor of hematopoietic origin |
| 02/26/2009 | US20090053224 Lox and loxl2 inhibitors and uses thereof |